You are here

Study Evaluating SKI-606 in Subject With Solid Tumors

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-74 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Advanced or recurrent solid malignancy confirmed histologically or cytologically for
which no effective therapy is available

2. Recovery from acute adverse effects of prior therapies to £ Grade 1 (excluding
alopecia)

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

4. Adequate hepatic, renal, and bone marrow function

5. Age 20 to 74 years

6. Willingness of male and female subjects, who are not surgically sterile or
postmenopausal, to use reliable methods of birth control for the duration of the study
and for 6 months and 30 days after the last dose of test article for male and female,
respectively

7. Life expectancy of at least 12 weeks

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Use of any systemic antitumor agents or any investigational agent within 28 days
before the enrollment (42 days if the previous chemotherapy included nitrosoureas or
mitomycin C)

2. Ongoing clinical requirement for administration of a strong inhibitor of CYP3A4

3. Prior exposure to SKI-606 or any other Src-kinase inhibitor

4. Major surgery or radiotherapy within 2 weeks before the enrollment (recovery from
previous surgery should be complete before day 1)

5. Subjects unable or unwilling to swallow SKI-606 capsules

6. Active central nervous system (CNS) metastases, as indicated by clinical symptoms,
cerebral edema, requirement for corticosteroids and/or progressive growth

7. Recent or ongoing clinically-significant gastrointestinal disorder

8. Pregnant or breastfeeding women

9. Subjects who meet the following criteria:

- Evidence of serious active infection, significant medical or psychiatric illness

- History of unexplained syncope or known ventricular arrythmia

- Known seropositivity to HIV, or current or chronic Hepatitis B or Hepatitis
hepatitis C

- Hypokalemia

- Unstable concurrent medical conditions

- Any other condition that, in the investigator's judgment, make the subject
inappropriate for this study the subject inappropriate for this study

NCT01001936
Pfizer
Completed
Study Evaluating SKI-606 in Subject With Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
San Antonio, Texas

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now